PTC Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTCT research report →
Range $75 – $137
Price Chart
About the company
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
- CEO
- Matthew Klein
- IPO
- 2013
- Employees
- 991
- HQ
- Warren, NJ, US
Get TickerSpark's AI analysis on PTCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.71B
- P/E
- -46.08
- Fwd P/E
- 107.25
- PEG
- 0.65
- P/S
- 4.36
- P/B
- -26.35
- EV/EBITDA
- 29.63
- Div Yield
- 0.00%
- Gross Margin
- 92.39%
- Op Margin
- 11.97%
- Net Margin
- -9.17%
- ROE
- 57.10%
- ROIC
- 5.66%
Latest fiscal year · YoY change
- Revenue
- $1.73B+114.5%
- Gross Profit
- $1.66B+121.4%
- Op Income
- $856.51M
- Net Income
- $682.64M+287.9%
- EPS
- $8.58+281.4%
- OCF Growth
- +760.4%
- FCF Growth
- +326.0%
- 52W High
- $90.87
- 52W Low
- $56.18
- 50D MA
- $63.45
- 200D MA
- $69.87
- Beta
- 0.51
- RSI (14)
- 34
- Avg Volume
- 1.07M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PTC Therapeutics posted record Q3 product revenue on Sephience momentum, raised full-year revenue guidance, and said it remains on track for cash flow breakeven in 2026.· October 29, 2026
- Q3 total revenue was $358 million, including $276 million of product revenue; product revenue was up over 100% year over year from $131 million in Q3 2025.
- Sephience was the main driver, generating $182 million in Q3 and topping 2,000 active patients worldwide after one year on the market.
- Management raised 2026 guidance to $960 million to $990 million in product revenue and $1.29 billion to $1.32 billion in total revenue.
- The company said it still expects cash flow breakeven in 2026, supported by expense control and a $2.13 billion cash balance.
- PTC also advanced its pipeline: ST-920 BLA filing is targeted for Q4 2026, votoplam’s FDA Type C meeting moved to Q1 2027, and PROVE-FA was initiated for vatiquinone.
PTC reported third-quarter 2026 total revenue of $358 million, with $276 million of product revenue versus $131 million in Q3 2025, representing over 100% year-over-year growth. Sephience net product revenue was $182 million; DMD franchise revenue was $74 million, including Translarna at $49 million and Emflaza at $25 million. Royalty revenue from Evrysdi was $82 million. Non-GAAP R&D expense was $95 million versus $91 million a year ago, and non-GAAP SG&A was $67 million versus $74 million a year ago. Cash, cash equivalents and marketable securities were $2.13 billion at September 30, 2026, versus $1.95 billion at December 31, 2025. Management raised full-year 2026 product revenue guidance to $960 million to $990 million and total revenue guidance to $1.29 billion to $1.32 billion, and reiterated expectations to reach cash flow breakeven in 2026.
Matthew Klein’s message was upbeat and centered on Sephience as a launch that has exceeded expectations but is still early. He said the company has built a broad patient base, that the vast majority of U.S. PKU patients still have not tried Sephience, and that the brand could still become a $2 billion-plus product. He also highlighted progress across the pipeline, including ST-920, votoplam, vatiquinone, and earlier-stage programs, framing the company as having multiple growth shots beyond PKU.
Pierre Gravier focused on the financial upside from commercial execution and disciplined spending. He cited $358 million of total revenue, $276 million of product revenue, $95 million of non-GAAP R&D, $67 million of non-GAAP SG&A, and a $2.13 billion cash balance. He said the ST-920 acquisition cost $111 million upfront with up to $100 million in contingent milestones, described it as value-accretive, and said it preserves flexibility for more business development and the path to cash flow breakeven and long-term profitability.
Analysts pressed management on whether Sephience growth was slowing in the U.S. and how the U.S./ex-U.S. mix could evolve. Management said the U.S. is still in a steady growth phase, not a slowdown, and that the majority of revenue should ultimately come from the U.S., while ex-U.S. growth should accelerate as more countries gain pricing and reimbursement. Questions also focused on pricing negotiations in Germany, France, Spain and Italy, where management said Germany should resolve soon and the other markets are likely to finalize in the first half of 2027. On ST-920, management described strong patient and payer interest, said the U.S. is the first focus, and noted that the asset could be accretive in 2027.
The bull case from this call is that Sephience is scaling faster than expected, with over 2,000 active patients and continued room to grow in both the U.S. and abroad. Management pointed to strong adherence, increasing switch activity, and new expansion channels like ambassadors, digital outreach, and upcoming geographic rollouts. The balance sheet is strong at $2.13 billion, and the company now has multiple late-stage or near-term catalysts, including ST-920 and votoplam.
The main risks discussed are that Sephience still has a long runway to prove durable penetration and that ex-U.S. revenue depends on reimbursement and pricing negotiations that are not yet finalized in several markets. Management also said the DMD franchise is facing pressure from a new generic entrant for Emflaza and does not expect large government purchase orders for Translarna in Q4 like the one seen in Q3. Pipeline timing remains dependent on regulators, with votoplam’s FDA meeting pushed into Q1 2027 and ST-920 still awaiting a Q4 2026 filing and later approval.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.3%
- Shares Outstanding
- 83.54M
- Float Shares
- 73.77M
of shares held by institutions
394 13F filers
Buy/sell ratio 0.30. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 14.40M | ▲ 432.76K |
| Vanguard Group Inc | 8.80M | ▲ 514.20K |
| Rtw Investments, LP | 7.75M | 0 |
| Jupiter Topco LLC | 7.24M | ▲ 7.24M |
| Janus Henderson Group Ltd. | 7.19M | ▲ 2.34M |
| State Street Corp | 5.51M | ▲ 913.60K |
| Vanguard Portfolio Management LLC | 4.98M | ▲ 50.09K |
| Wellington Management Group Llp | 4.13M | ▲ 185.66K |
| Vanguard Capital Management LLC | 3.62M | ▼ 120.63K |
| Westfield Capital Management Co LP | 2.70M | ▲ 743.18K |
| Toronto Dominion Bank | 2.17M | ▼ 860.12K |
| Geode Capital Management, LLC | 2.15M | ▼ 59.39K |
Held by 471 ETFs
Biggest fund positions in PTCT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Boulding Mark Elliott | other | 2,812 |
| Nov 16, 26 | Boulding Mark Elliott | sell | 1,315 |
| Nov 16, 26 | Boulding Mark Elliott | sell | 1,288 |
| Nov 16, 26 | Boulding Mark Elliott | sell | 209 |
| Nov 16, 26 | Boulding Mark Elliott | other | 2,812 |
| Oct 14, 26 | SCHMERTZLER MICHAEL | sell | 2,118 |
| Oct 14, 26 | SCHMERTZLER MICHAEL | sell | 382 |
| Oct 9, 26 | Boulding Mark Elliott | other | 192 |
| Oct 9, 26 | Boulding Mark Elliott | sell | 192 |
| Oct 9, 26 | Boulding Mark Elliott | other | 192 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTCT coverage
Recent articles, reports, and earnings notes.

Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.

Clinuvel Pharmaceuticals Limited IPO Preview: Nasdaq ADR Upgrade
Clinuvel Pharmaceuticals Limited American Depositary Shares are expected to list on NASDAQ on 2026-07-20, but the price range has not been disclosed. The setup looks more like an ADR listing upgrade than a classic new-money IPO, with an established profitable specialty pharma business behind it.
Want a deeper read on PTCT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
marketbeat.com · Nov 16
PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows
seekingalpha.com · Nov 3
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
prnewswire.com · Nov 3
PTC Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 2
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Oct 30
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
PTC Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Oct 29
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.